This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Zacks12-11

Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor. Should You Buy #1 (Strong Buy)-Ranked Veracyte (VCYT) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490786278?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9","is_english":true,"pubTime":"2024-12-11 22:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490786278","market":"us","top_or_hot":-1,"title":"This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar","media":"Zacks","content":"<div>\n<p>Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor.\nShould You Buy #1 (Strong Buy)-Ranked Veracyte (VCYT) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-medical-stock-1-strong-144005864.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/top-medical-stock-1-strong-144005864.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor.\nShould You Buy #1 (Strong Buy)-Ranked Veracyte (VCYT) ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-medical-stock-1-strong-144005864.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/top-medical-stock-1-strong-144005864.html","article_id":"2490786278","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490786278","pubTimestamp":1733928005,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor.Should You Buy #1 -Ranked Veracyte  for Your Portfolio?Veracyte was upgraded to the Zacks Rank #1 list on November 20, 2024. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way to get into stocks highly sought after by institutional investors.Headquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma , Decipher Prostate , Prosigna , Envisia  and Decipher Bladder , with additional tests in development.Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VCYT":"Veracyte Inc"},"translate_title":"这只顶级医疗股票是#1（强力买入）：为什么它应该引起您的关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":0.9},"content_text":"Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor.\nShould You Buy #1 (Strong Buy)-Ranked Veracyte (VCYT) for Your Portfolio?\nVeracyte was upgraded to the Zacks Rank #1 list on November 20, 2024. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way to get into stocks highly sought after by institutional investors.\nHeadquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), Envisia (interstitial lung diseases) and Decipher Bladder (bladder cancer), with additional tests in development.\nThree analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.25 to $0.38 per share. VCYT boasts an average earnings surprise of 520.6%.\nEarnings are forecasted to see growth of 137.3% for the current fiscal year, and sales are expected to increase 22.9%.\nAdditionally, VCYT has climbed higher over the past four weeks, gaining 12.4%. The S&P 500 is up 0.8% in comparison.\nBottom Line\nWith a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Veracyte could be just the stock to help your portfolio generate returns that could fund your retirement, your kids' college tuition, or your short- and long-term savings goals.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490786278"}